Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sarepta Therapeutics (SRPT) and Ironwood Pharma (IRWD).
Sarepta Therapeutics (SRPT)
In a report released today, Debjit Chattopadhyay from H.C. Wainwright maintained a Buy rating on Sarepta Therapeutics, with a price target of $267. The company’s shares closed on Friday at $121.38.
Chattopadhyay noted:
“Our $267 price target is derived from a risk-adjusted (does not include CMT or Sanfilippo A) DCF analysis and is based on: beta of 1.41, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 7.4%, and tax rate of 15% beginning in FY 2024.”
According to TipRanks.com, Chattopadhyay is ranked 0 out of 5 stars with an average return of -6.6% and a 38.6% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Mersana Therapeutics Inc, and Voyager Therapeutics Inc.
Currently, the analyst consensus on Sarepta Therapeutics is a Strong Buy with an average price target of $197.11, representing a 62.4% upside. In a report issued on November 26, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $217 price target.
.
See today’s analyst top recommended stocks >>
Ironwood Pharma (IRWD)
H.C. Wainwright analyst Ram Selvaraju reiterated a Sell rating on Ironwood Pharma today and set a price target of $11.50. The company’s shares closed on Friday at $12.31, close to its 52-week low of $11.02.
Selvaraju said:
“We have accordingly lowered our 2018 revenue expectations to $308.3M vs. the previous $342.3M. The bottom-line result also missed our projection, coming in at a loss per share of $1.14 vs. our estimate of a loss per share of $0.97. As we had previously pointed out, Ironwood recorded a $151M impairment charge related to the return of the lesinurad assets to AstraZeneca (AZN; not rated), its erstwhile licensor. The company also indicated that its U.S. licensing partner Allergan plc (AGN; not rated) had hit it with a $59M adjustment to Lenzess net sales, truing up estimates to actual subsequent payments made for the three-year period between 2015 and 2017.”
According to TipRanks.com, Selvaraju ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -14.0% and a 19.8% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
Currently, the analyst consensus on Ironwood Pharma is a Hold with an average price target of $15.14.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
